Inovio Pharmaceuticals (INO) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.
The company said all study participants "maintained biologically relevant levels of DMAbs" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.
The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca (AZN), and clinical investigators at the University of Pennsylvania.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.